The aim of our study was to evaluate the clinical usefulness of the tumor markers CEA, CA 125 and PSA using the COBAS CORE system from Roche Diagnostic Systems. Our results demonstrate that determination of these markers on the COBAS CORE immunoassasy analyser provides the performance required for routine use in clinical practice. The results obtained in this clinical trial validate the correlation with disease extension, a characteristic that defines and determines the clinical utility of the tumor markers. We also conclude that learning to operate the COBAS CORE system is simple, as is management of the system through the user-friendly software.
BallestaA., MolinaR.Tumor markers: definition and classification. In: BallestaA., TorreG.C., BombardieriE., GionM., MolinaR., eds. Updating on tumor markers in tissues and in biological fluids.Torino: Ed. Minerva Medica, 1993; 75–88.
2.
WaldmanT.A., HebermanR.H.Tumor markers in diagnosis and in monitoring therapy. In: HollandJ.F., FreiE., eds. Cancer medicine.Philadelphia: Lea & Febiger, 1982; 1068–89.
3.
MintonJ.P., MartinE.W.The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look operation. Cancer1978; 42: 1422–7.
4.
FilellaX., MolinaR., GrauJ.J.Prognostic vaue of CA 19.9 levels in colorectal cancer. Ann Surg1992; 216: 278–86.
5.
MolinaR., JoJ., FilellaX.Mucin-like carcinoma-associated antigen (MCA) in tissue and serum of patients with breast cancer: clinical applications in prognosis and disease monitoring. Int J Biol Markers1993; 8: 113–23.
6.
CatalonaW.J., SmithD.S., RatliffT.L.Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med1991; 324: 1156–61.
7.
LabrieF., DupontA., SuburuR.Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol1992; 147: 846–52.
8.
SijorskaH.M., FuksA., GoldP.Clinical applications of carcinoembryonic antigen. J Nucl Med Allied Sci1990; 34(suppl. 3): 7–29.
9.
BastR.C., KlingT.L., St JohnE.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med1983; 309: 883–7.
10.
OesterlingJ.E., JacobsenS.J., ChuteC.G.Serum prostate-specific antigen in a community-based population of healthy men. JAMA1993; 270: 860–4.
11.
BeaudonnetA., GounonG., PichotJ., RevenantM.C.Sex-and age-related influences on carcinoembryonic antigen in blood. Clin Chem1981; 27: 771.
12.
StockeyR.A., ShawJ., WhitfieldA.G.W., WhiteheadT.P., ClarkeC.A.Effect of cigarette smoking, pulmonary inflammation and lung disease on concentrations of carcinoembryonic antigen in serum and secretions. Thorax1986; 41: 17–24.
13.
DietelM., ArpsH., KlapdorR.Antigen detection by the monoclonal antibody CA 19.9 and CA125 in normal and tumour tissue and patient sera. J Cancer Res Clin Oncol1986; 111: 257–65.
14.
QueraltóJ.M., BoydJ.C., HarrisE.K.On the calculation of reference change values, with examples from a long-term study. Clin Chem1993; 39: 1398–403.
15.
MoraJ., QueraltóJ.M., GascónN., GonzalezF.Reference change values to follow-up oncologic patients. XXII ISOBM Meeting. Groningen, 1994; P 17.1: 263.
16.
FilellaX., MolinaR., PiquéJ.M.CEA as a prognostic factor in colorectal cancer. Anticancer Res1994; 14: 705–8.
17.
MolinaR., OjedaB., FilellaX.A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumor Biol1992; 13: 278–86.
18.
FilellaX., MolinaR., JoJ.Clinical usefulness of prostate specific antigen and prostatic acid phosphatase in patients with prostatic cancer. Tumor Biol1990; 11: 289–94.
AlcoverJ., FilellaX., BarrancoM.A., MolinaR., BallestaA.M., CarreteroP.False positive values of PAP and PA in complicated and non-complicated benign prostatic hypertrophy. Arch It Urol1993; 65: 491–4.
21.
FilellaX., AlcoverJ., MolinaR., CarrereW., CarreteroP., BallestaA.M.Usefulness of prostate specific antigen density as a diagnostic test of prostate cancer. Tumor Biol1996; 17: 20–6.
